

25. (Amended) A polypeptide from a phage display that can bind to the polypeptide according to claim 23.

26. (Amended) An isolated polypeptide having at least 90% homology to SEQ ID NO:38 according to claim 23 and wherein said polypeptide is a human mRNA putatively prenylated protein .

27. (Amended) A method for finding an active ingredient against hystero myoma comprising measuring the binding of said ingredient to the isolated polypeptide sequence comprising SEQ ID NO:38 according to claim 23.

28. (Amended) A method for finding an active ingredient against hystero myoma comprising measuring the binding of said ingredient to the polypeptide encoded by the nucleic acid comprising SEQ ID NO:16.

29. (Amended) The nucleic acid comprising SEQ ID NO:16 according to claim 28, wherein said sequence is in the sense or antisense form.

30. (Amended) A method for treating hystero myoma comprising administering a therapeutically effective amount of a polypeptide comprising SEQ ID NO:38 according to claim 23.

31. (Amended) A method for preparing a pharmaceutical composition for treating hystero myoma comprising mixing a pharmaceutically acceptable carrier with a polypeptide comprising SEQ ID NO:38 according to claim 23.

Please **ADD** the following new claims:

--39. A method for determining whether a compound is active against hysterosmyoma comprising measuring the binding of said ingredient to the isolated polypeptide according to claim 24.

40. A method for determining whether a compound is active against hysterosmyoma comprising measuring the binding of said ingredient to the isolated polypeptide according to claim 26. --